Efficacy and safety of the anti-TNF biologic agents

References

• Aggarwal BB. Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol 2003;3:745–56.
   PubMed Web of Science ®Google Scholar
• Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001;344:907–16.
   PubMed Web of Science ®Google Scholar
• Nawroth PP, Bank I, Handley D, Cassimeris J, Chess L, Stern D. Tumor necrosis factor/cachectin interacts with endothelial cell receptors to induce release of interleukin 1. J Exp Med 1986;163: 1363–75.
   PubMed Web of Science ®Google Scholar
• Chu CQ, Field M, Allard S, Abney E, Feldmann M, Maini RN. Detection of cytokines at the cartilage/pannus junction in patients with rheumatoid arthritis: implications for the role of cytokines in cartilage destruction and repair. Br J Ftheumatol 1992;31:653–61.
   PubMedGoogle Scholar
• Deleuran BW, Chu CQ, Field M, Brennan FM, Mitchell T, Feldmann M, et al. Localization of tumor necrosis factor receptors in the synovial tissue and cartilage-pannus junction in patients with rheumatoid arthritis. Implications for local actions of tumor necro-sis factor alpha. Arthritis Rheum 1992;35:1170–8.
   Google Scholar
• Husby G, Williams RC Jr. Synovial localization of tumor necrosis factor in patients with rheumatoid arthritis. J Autoimmun 1988;1: 363–71.
   PubMed Web of Science ®Google Scholar
• Saxne T, Palladino MA Jr, Heinegard D, Tata' N, Wollheim FA. Detection of tumor necrosis factor alpha but not tumor necrosis factor beta in rheumatoid arthritis synovial fluid and serum. Arthri-tis Rheum 1988;31:1041–5.
   Google Scholar
• Tetta C, Camussi G, Modena V, Di Vittorio C, Baglioni C. Tumour necrosis factor in serum and synovial fluid of patients with active and severe rheumatoid arthritis. Ann Rheum Dis 1990;49: 665–7.
   Google Scholar
• Butler DM, Maini RN, Feldmann M, Brennan FM. Modulation of proinflammatory cytokine release in rheumatoid synovial mem-brane cell cultures. Comparison of monoclonal anti TNF-alpha antibody with the interleukin-1 receptor antagonist. Eur Cytokine Netw 1995;6:225–30.
   Google Scholar
• Haworth C, Brennan FM, Chantry D, Turner M, Maini RN, Feldmann M. Expression of granulocyte-macrophage colony-stimulating factor in rheumatoid arthritis: regulation by tumor ne-crosis factor-alpha. Eur J Immunol 1991;21:2575–9.
   PubMed Web of Science ®Google Scholar
• Proudman SM, Cleland LG, Mayrhofer G. Effects of tumor necro-sis factor-alpha, interleukin 1-beta, and activated peripheral blood mononuclear cells on the expression of adhesion molecules and recruitment of leukocytes in rheumatoid synovial xenografts in SCID mice. J Ftheumatol 1999;26: 1877–89.
   Google Scholar
• Clavel G, Bessis N, Boissier MC. Recent data on the role for angiogenesis in rheumatoid arthritis. Joint Bone Spine 2003;70: 321–6.
   Google Scholar
• FitzGerald 0, Soden M, Yanni G, Robinson R, Bresnihan B. Morphometric analysis of blood vessels in synovial membranes obtained from clinically affected and unaffected knee joints of 34. patients with rheumatoid arthritis. Ann Rheum Dis 1991;50: 792–6.
   Google Scholar
• Pando JA, Duray P, Yarboro C, Gourley MF, Klippel JH, Schumacher HR. Synovitis occurs in some clinically normal and 35. asymptomatic joints in patients with early arthritis. J Ftheumatol 2000;27:1848–54.
   Google Scholar
• Goldring SR. Pathogenesis of bone and cartilage destruction in rheumatoid arthritis. Ftheumatology (Oxford) 2003;42 Suppl 36. 2:iill-ii16.
   Google Scholar
• Collin-Osdoby P, Rothe L, Anderson F, Nelson M, Maloney W, Osdoby P. Receptor activator of NF-kappa B and osteoprotegerin expression by human microvascular endothelial cells, regulation by 37. inflammatory cytokines, and role in human osteoclastogenesis. J Biol Chem 2001;276: 20659–72.
   Google Scholar
• Tsuboi M, Kawakami A, Nakashima T, Matsuoka N, Urayama S, Kawabe Y, et al. Tumor necrosis factor-alpha and interleukin-1-38. beta increase the Fas-mediated apoptosis of human osteoblasts. J Lab Clin Med 1999;134:222–31.
   PubMedGoogle Scholar
• Saklatvala J. Tumour necrosis factor alpha stimulates resorption and inhibits synthesis of proteoglycan in cartilage. Nature 1986;322:547-9.39.
   Google Scholar
• Henderson B, Pettipher ER. Arthritogenic actions of recombinant IL-1 and tumour necrosis factor alpha in the rabbit: evidence for synergistic interactions between cytokines in vivo. Clin Exp Immunol 1989;75:306-10.40.
   Google Scholar
• Reginato AM, Sanz-Rodriguez C, Diaz A, Dharmavaram RM, Jimenez SA. Transcriptional modulation of cartilage-specific col-lagen gene expression by interferon gamma and tumour necrosis factor alpha in cultured human chondrocytes. Biochem J 1993;294: 761–9.
   Web of Science ®Google Scholar
• Thorbecke GJ, Shah R, Leu CH, Kuruvilla AP, Hardison AM, 41. Palladino MA. Involvement of endogenous tumor necrosis factor alpha and transforming growth factor beta during induction of collagen type II arthritis in mice. Proc Natl Acad Sci USA 1992; 89:7375-9.42.
   Google Scholar
• Williams RO, Feldmann M, Maini RN. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci USA 1992;89:9784–8.
   Google Scholar
• Wooley PH, Dutcher J, Widmer MB, Gillis S. Influence of a recom- 43. binant human soluble tumor necrosis factor receptor FC fusion protein on type II collagen-induced arthritis in mice. J Immunol 1993;151:6602–7.
   Google Scholar
• Keffer J, Probert L, Cazlaris H, Georgopoulos S, Kaslaris E, Kioussis D, et al. Transgenic mice expressing human tumour ne- 44. crosis factor: a predictive genetic model of arthritis. EMBO J 1991; 10:4025–31.
   Google Scholar
• Humira (adalimumab) [package insert]. 2003. North Chicago; Abbott Laboratories.
   Google Scholar
• Remicade (infliximab) recombinant for IV injection [package in- 45. sert]. 2003. Malvern: Centocor.
   Google Scholar
• Enbrel (etanercept) [package insert]. 10-17-2003. Thousand Oaks: Immunex Corporation.
   Google Scholar
• Haak-Frendscho M, Marsters SA, Mordenti J, Brady S, Gillett NA, Chen SA, et al. Inhibition of TNF by a TNF receptor 46. immunoadhesin. Comparison to an anti-TNF monoclonal anti-body. J Immunol 1994;152: 1347–53.
   Google Scholar
• Zhou H, Buckwalter MMP, Raible D, Wajdula J, Fatenejad S, Sanda M. Pharmacokinetics (PK) of etanercept are unaltered by 47. concurrent administration of methotrexate (MTX) in rheumatoid arthritis (RA) patients [abstract]. ACR 67th Annual Meeting 2003;253.
   Google Scholar
• ScaHon BJ, Moore MA, Trinh H, Knight DM, Ghrayeb J. Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant 48. transmembrane TNF-alpha and activates immune effector func-tions. Cytokine 1995;7: 251–9.
   Google Scholar
• Maini RN, Feldmann M. How does infliximab work in rheumatoid arthritis? Arthritis Res 2002;4 Suppl 2:S22–S28.49.
   Google Scholar
• Salfeld J, Kaymakcalan Z, Tracey D, Roberts A, Kamen R. Gen-eration of fully human anti-TNF antibody D2E7 [abstract]. Arthri-tis Rheum 1998;41(Suppl):557.
   Google Scholar
• Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, et al. A comparison of etanercept and methotrexate 50. in patients with early rheumatoid arthritis. N Engl J Med 2000; 343:1586–93.
   Google Scholar
• Genovese MC, Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum 2002;46:1443–50.
   PubMed Web of Science ®Google Scholar
• Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver AL, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997;337:141–7.
   PubMed Web of Science ®Google Scholar
• Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ, et al. Etanercept therapy in rheuma-toid arthritis. A randomized, controlled trial. Ann Intern Med 1999;130:478–86.
   PubMed Web of Science ®Google Scholar
• Kremer JM, Weinblatt ME, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Jackson CG, et al. Etanercept added to back-ground methotrexate therapy in patients with rheumatoid arthritis: continued observations. Arthritis Rheum 2003;48:1493–9.
   PubMed Web of Science ®Google Scholar
• Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, et al. A trial of etanercept, a recombi-nant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340:253–9.
   PubMed Web of Science ®Google Scholar
• Wells GA, Tugwell P, Kraag GR, Baker PR, Groh J, Redelmeier DA. Minimum important difference between patients with rheu-matoid arthritis: the patient's perspective. J Ftheumatol 1993;20: 557–60.
   Google Scholar
• Rothschild A, Petkus D. New data show many rheumatoid arthritis patients treated with Enbrel plus methotrexate have expe-rienced clinical remission and most had no progression of joint damage [press release]. Available at: http://www.immunex.com/ news/news03/pressRelease031024b.pdf. Accessed October 24, 2003.
   Google Scholar
• Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, et al. Randomised double-blind comparison of chimeric mono-clonal antibody to tumour necrosis factor alpha (cA2) versus pla-cebo in rheumatoid arthritis. Lancet 1994;344:1105–10.
   PubMed Web of Science ®Google Scholar
• Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, 13fil H, et al. Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis. Lancet 1994;344: 1125–7.
   Google Scholar
• Maini RN, Breedveld FC, Kalden JR, Smolen J, Davis D, Macfarlane JD, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;41:1552–63.
   PubMed Web of Science ®Google Scholar
• Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis pa-tients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999;354:1932–9.
   PubMed Web of Science ®Google Scholar
• Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000;343:1594–602.
   Google Scholar
• Rau R. Adalimumab (a fully human anti-tumour necrosis factor alpha monoclonal antibody) in the treatment of active rheumatoid arthritis: the initial results of five trials. Ann Rheum Dis 2002;61 Suppl 2:ii70-ii73.
   Google Scholar
• Burmester GR, Van de Putte LBA, Rau R, Breedveld FC, Kalden JR, Malaise M, et al. Long-term efficacy and safety of adalimumab (D2E7) monotherapy in patients with DMARD-refractory rheu-matoid arthritis: results from a 2-year study [abstract]. Arthritis Rheum 2002;Supp1:1436.
   Google Scholar
• Van de Putte LBA, Atkins C, Malaise M, Sany J, Russell AS, van Rid PCL, et al. Adalimumab (D2E7) monotherapy in the treatment of patients with severely active rheumatoid arthritis [abstract]. Arthritis Rheum 2002;45(Suppl):Abstract 456.
   Google Scholar
• Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003;48:35–45.
   PubMed Web of Science ®Google Scholar
• Keystone E, Kavanaugh AF, Sharp J, Hua Y, Teoh L, Fischkoff S, et al. Adalimumab (D2E7), a fully human anti-TNF-a monoclonal antibody, inhibits the progression of structural joint damage in patients with active RA despite concomitant methotrexate therapy [abstract]. Arthritis Rheum 2002;46(Suppl):S205.
   Google Scholar
• Singh G, Ramey DR, Rausch PI, Schettler JD. Serious infection in rheumatoid arthritis: relationship to immunosuppressive use [abstract]. Arthritis Rheum 1999;42\(suppl 9):5242.
   Google Scholar
• Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Frequency of infection in patients with rheumatoid arthritis com-pared with controls: a population-based study. Arthritis Rheum 2002;46:2287–93.
   Google Scholar
• Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Predictors of infection in rheumatoid arthritis. Arthritis Rheum 2002;46:2294–300.
   PubMed Web of Science ®Google Scholar
• Baecklund E, Ekbom A, Sparen P, Feltelius N, Klareskog L. Dis-ease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study. BMJ 1998;317:180–1.
   Google Scholar
• Prior P. Cancer and rheumatoid arthritis: epidemiologic consider-ations. Am J Med 1985;78:15–21.
   Google Scholar
• Prior P, Symmons DP, Hawkins CF, Scott DL, Brown R. Cancer morbidity in rheumatoid arthritis. Ann Rheum Dis 1984;43:128–31.
   PubMed Web of Science ®Google Scholar
• Myllykangas-Luosujarvi R, Aho K, Isomaki H. Mortality from cancer in patients with rheumatoid arthritis. Scand J Ftheumatol 1995;24:76–8.
   PubMed Web of Science ®Google Scholar
• Moreland LW, Cohen SB, Klareskog L, Burge DJ. Global safety and efficacy of more than 5 years of etnercept (ENBREL) therapy. 67th Annual Meeting of the American College of Ftheumatology 2003;Abstract 215.
   Google Scholar
• Lipsky P, Van der Heijde D, St Clair W, Smolen J, Furst D, Kalden J, et al. 102-wk clinical and radiologic results from the ATTRACT trial: a 2 year, randomized, controlled, phase 3 trial of infliximab (Remicade) in pts with active RA despite MTX. Arthritis Rheum 2000;43(Suppl), Abstract 1216.
   Google Scholar
• Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:1098–104.
   Google Scholar
• Lee JH, Slifman NR, Gershon SK, Edwards ET, Schwieterman WD, Siegel JN, et al. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept. Arthritis Rheum 2002;46:2565–70.
   PubMed Web of Science ®Google Scholar
• Ruderman EM, Markenson JA. Granulomatous infections and tumor necrosis factor antagonist therapies: update through June 2002. 67th Annual Meeting of the American College of Ftheuma-tology 2003; Abstract 541.
   Google Scholar
• Ehlers S. Role of tumour necrosis factor (TNF) in host defence against tuberculosis: implications for immunotherapies targeting TNF. Ann Rheum Dis 2003;62 Suppl 2:ii37-ii42.
   Google Scholar
• Scanon B, Cai A, Solowski N, Rosenberg A, Song XY, Shealy D, et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 2002;301:418–26.
   Google Scholar
• Lugering A, Schmidt M, Lugering N, Pauels HG, Domschke W, Kucharzik T. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology 2001;121:1145–57.
   PubMed Web of Science ®Google Scholar